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Abstract
Furosemide is a potent loop diuretic commonly and variably used by neonatologists to improve oxygenation and
lung compliance in premature infants. There are several safety concerns with use of furosemide in premature
infants, specifically the risk of sensorineural hearing loss (SNHL), and nephrocalcinosis/nephrolithiasis (NC/NL). We
conducted a systematic review of all trials and observational studies examining the association between these
outcomes with exposure to furosemide in premature infants.
We searched MEDLINE, EMBASE, CINAHL, and clinicaltrials.gov. We included studies reporting either SNHL or NC/NL
in premature infants (< 37 weeks completed gestational age) who received at least one dose of enteral or
intravenous furosemide. Thirty-two studies met full inclusion criteria for the review, including 12 studies examining
SNHL and 20 studies examining NC/NL. Only one randomized controlled trial was identified in this review. We
found no evidence that furosemide exposure increases the risk of SNHL or NC/NL in premature infants, with
varying quality of studies and found the strength of evidence for both outcomes to be low. The most common
limitation in these studies was the lack of control for confounding factors.
The evidence for the risk of SNHL and NC/NL in premature infants exposed to furosemide is low. Further
randomized controlled trials of furosemide in premature infants are urgently needed to adequately assess the risk
of SNHL and NC/NL, provide evidence for improved FDA labeling, and promote safer prescribing practices.
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Background
Furosemide is a potent diuretic that acts in the proximal
and distal tubules, as well as the loop of Henle, to inhibit
sodium and chloride reabsorption in the kidneys. The
use of diuretics such as furosemide may alleviate symp-
toms associated with volume overload, including
pulmonary edema. In premature infants, early pulmon-
ary edema and excessive intravenous fluid administration
are associated with an increased risk of bronchopulmon-
ary dysplasia (BPD), also called chronic lung disease of
prematurity [1, 2]. Therefore, furosemide may be part of
a clinical approach to reducing the risk of BPD in pre-
mature infants.
The Food and Drug Administration (FDA) has
approved furosemide for the treatment of edema associ-
ated with congestive heart failure, cirrhosis, and neph-
rotic syndrome in children and adults. Furosemide is not
approved by the FDA for use in premature infants and,
as a result, any use in this population is considered
off-label. Specifically, the FDA label for furosemide
includes a warning that infants < 31 weeks postmenstr-
ual age receiving doses > 1 mg/kg/day intravenously may
develop plasma levels resulting in ototoxicity. The label
also notes that renal function monitoring and renal
sonography should be considered in premature infants,
as furosemide may precipitate nephrocalcinosis.
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The primary safety concern of furosemide use in pre-
mature infants is sensorineural hearing loss (SNHL).
The incidence of SNHL is approximately 0.7–1.5%
among infants admitted to the NICU and is more com-
mon in infants born prematurely [3, 4]. The association
of SNHL and furosemide relies heavily on studies con-
ducted in adults receiving high doses of furosemide. In
one study, reversible hearing loss occurred in 50% of
adult patients with uremia given a single 1000 mg intra-
venous dose of furosemide, which is 50 times the usual
adult dose [5]. A case series reported transient deafness
in 3 adult patients with renal impairment given intraven-
ous doses of 2000–3000 mg [6]. Finally, a trial of 19
adult patients receiving furosemide or placebo resulted
in one patient with permanent deafness who had
received 14 days of 1000 mg per day. The authors of
the trial reported that furosemide levels > 100 μg/mL
were associated with ototoxicity [7]. The proposed
mechanisms for furosemide-induced ototoxicity in-
clude changes in potassium concentrations in the
cochlear endolymph and impairment of cellular
proliferation [8, 9].
Furosemide use in premature infants has also been
implicated in the development of nephrocalcinosis and
nephrolithiasis, or renal calcifications and stones, al-
though the etiology in this population is likely to be
multifactorial [10, 11]. Nephrocalcinosis is diagnosed by
renal ultrasonography and has the appearance of
increased echogenicity in the medullary pyramids of the
kidney. Renal calculi, or nephrolithiasis, are detected on
ultrasound by echogenic foci in the calyces or renal
pelvis. Loop diuretics, such as furosemide, reduce renal
tubular reabsorption of calcium resulting in hypercalci-
uria, which is the proposed mechanism for its associ-
ation with nephrocalcinosis. However, this association is
often confounded by concomitant exposure to other
therapies, such as dexamethasone, long-term parenteral
nutrition, and mechanical ventilation, which have been
identified as risk factors for renal calcifications [12, 13].
In the absence of robust data from large, well-powered
clinical trials, the best available method for evaluating
the safety of furosemide in premature infants includes a
thorough review of the limited number of randomized
control trials, as well as non-controlled studies such as
cohort and case-control studies. This systematic review
will synthesize all trials and observational studies in
which premature infants were exposed to at least one
dose of furosemide and report on the following out-
comes: SNHL and nephrocalcinosis/nephrolithiasis (NC/
NL). This review differs from Cochrane reviews in its
inclusion of observational studies, which comprise the
majority of available evidence for furosemide safety in
premature infants. The key questions this systematic
review will address are the following:
Key Question 1: Does exposure to furosemide in
premature infants increase the risk of SNHL?
Key Question 2: Does exposure to furosemide in
premature infants increase the risk of NC/NL?
Methods
We reviewed all observational cohort studies or clinical
trials in which premature infants (< 37 weeks completed
gestational age) were exposed to at least one dose of
furosemide while hospitalized in the NICU. We used
premature infants without exposure to furosemide, when
available, as comparators. The outcomes of interest were
SNHL and NC/NL. Table 1 displays the eligibility
criteria for this systematic review.
We searched the following databases for the relevant
literature published in English: MEDLINE, EMBASE,
and CINAHL. We also searched clinicaltrials.gov to in-
clude results of unpublished studies. The references of
relevant articles within this search were reviewed by the
investigators for additional articles of interest. The date
of the most recent search was February 3, 2018. The
MEDLINE search used the following Medical Subject
Heading terms: “furosemide” AND “infant, premature.”
The final search included the following string of search
terms: “furosemide”[MeSH Terms] OR “furosemide”[All
Fields] AND “infant, premature”[MeSH Terms] OR
(“infant”[All Fields] AND “premature”[All Fields]) OR
“premature infant”[All Fields] OR “preterm”[All Fields]
AND “infant”[All Fields] OR “preterm infant”[All Fields]
OR “neonate”[All Fields]. The EMBASE and CINAHL
searches used the following terms: (‘premature infant’/exp.
OR ‘premature infant’ OR ((‘premature’/exp. OR prema-
ture) AND (‘infant’/exp. OR infant))) AND (‘furosemide’/
exp. OR furosemide). The clinicaltrials.gov search used
the terms “premature infant” and “furosemide.”
We compiled all studies resulting from the preceding
search strategy and removed duplicates. Two authors
(WJ and GT) reviewed titles and abstracts for relevance
using the software program Abstrackr [14]. We screened
Table 1 Eligibility Criteria
Patient/Population Infant < 37 weeks completed
gestational age
Intervention ≥1 dose of furosemide (IV or PO)
during hospitalization in the neonatal
intensive care unit
Control Infant < 37 weeks completed
gestational age without exposure
to furosemide
Outcomes sensorineural hearing loss;
nephrocalcinosis/nephrolithiasis
Study Design clinical trials, retrospective or
prospective cohort studies,
case-control studies
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full text articles and developed data abstraction forms
to determine eligibility of each study. If eligibility
criteria were met, we recorded the study design,
population characteristics, characteristics of compari-
son group, outcomes examined, sample size, duration
of follow-up, and funding sources. These data abstrac-
tion forms were used by the investigators to report
on the results (Additional file 1).
We assessed the quality (internal validity) of random-
ized controlled trials using the Cochrane Collaboration’s
tool for assessing risk of bias in clinical trials [15]. This
tool includes the assessment of randomization proce-
dures, allocation concealment, blinding of participants
and investigators, completeness of outcomes data, selective
reporting, and the risk of other biases. Each randomized
controlled trial included in the systematic review was
graded on each of these parameters as high risk of bias,
low risk of bias, or unclear risk of bias. We assessed the
risk of bias in non-randomized studies using the
ROBINS-1 tool, which assesses confounding biases, bias in
the selection of participants, classification biases, biases
due to deviations from intended interventions, missing
data biases, and biases in measurement of outcomes
[16]. Bias is rated on a scale of low, moderate, ser-
ious, or critical risk of bias, or no information. We
then graded the strength of the evidence for each key
question using guidance from the Evidence-based
Practice Center program of the U.S. Agency for
Healthcare Research and Quality [17].
The pre-specified outcome measures were odds ratios
and risk ratios, where appropriate, with 95% confidence
intervals for the exposure of furosemide in premature
infants with each of the outcomes of interest addressed
in the key questions. Results of each study were
described and only the information pertaining to the
outcomes of interest in the key questions were included.
Results
We identified 260 records through MEDLINE, 620
records through EMBASE, 51 records from CINAHL,
and 1 study from clinicaltrials.gov. After removing dupli-
cates, we screened 390 records for eligibility. We ex-
cluded 224 records due to study design, non-human
population, or non-English language. We reviewed the
full text of the remaining 166 articles and excluded 139
articles for inappropriate study population or lack of
relevant safety outcome. We identified 5 articles in the
reference lists of reviewed articles which met the eligibil-
ity criteria. These studies did not appear in the original
search due to the use of a variation in the drug name:
“frusemide”, instead of “furosemide.” In total, 32 articles
were included in the quantitative analysis. See Fig. 1 for
the PRISMA flow diagram.
Key question 1: Does exposure to furosemide in
premature infants increase the risk of sensorineural
hearing loss?
Only one randomized controlled trial of furosemide
compared to placebo in premature infants reported on
the outcome of SNHL [18]. In this trial, 24 premature
infants were randomized to receive either furosemide or
placebo for 7 days. The initial dose of furosemide (1 mg/
kg IV or 2 mg/kg orally every 12 h) was doubled after
48 h in infants where there was not a 50% increase in
urine output over 12 h. In the 17 infants available for
analysis (7 infants in treatment group and 10 infants in
the control group), no SNHL was detected prior to
discharge.
We identified 11 observational studies examining the
association of furosemide and SNHL in premature in-
fants: 5 retrospective cohort studies and 6 case-control
studies [19–29]. The results of the studies were mixed;
however, an association between furosemide and
SNHL was found in 8 of the 11 observational studies
[19–23, 25, 27, 29]. Two cohort studies and one
case-control study did not identify an association with
furosemide and SNHL [24, 26, 28]. These negative
studies were conducted in single centers and did not
consider dose exposure of furosemide.
Table 2 summarizes the population characteristics,
sample size, outcome measures, and results from each
study. The studies varied considerably in their defini-
tions of SNHL, including the type of auditory testing
used and length of follow-up. However, every study
included a hearing screen in all infants prior to NICU
discharge and every infant classified as having SNHL
failed the initial newborn hearing screen. Auditory test-
ing in these studies included either auditory brain stem
response (ABR) [19, 20, 22, 28], brainstem auditory
evoked response (BAER) [21], otoacoustic emission
(OAE) test [23], behavioral audiometry in older children,
or some combination of these tests [24–27, 29]. Several
studies differentiated auditory neuropathy or auditory
neuropathy spectrum disorders, in which there is a
defect in the transmission of sound from the inner hair
cells of the cochlea to the brain via the auditory nerve,
from the broader category of SNHL [25–27]. Infants
with auditory neuropathy have an abnormal ABR with
preserved OAE testing, while those with SNHL have
abnormal results on both tests.
Although a majority of the studies did not consider
dosing, three studies described the dose and duration of
furosemide and its association with SNHL and each of
these studies found a positive association between
furosemide and SNHL [20, 22, 27]. One found higher
cumulative dose exposure of furosemide in infants with
hearing loss than was true in infants without hearing
loss (mean +/− standard deviation: 139.1 +/− 130 mg/kg
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vs. 41.5 +/− 76 mg/kg; p < 0.001), in addition to longer
duration of furosemide use in the hearing loss group
(52.5 +/− 43 days vs. 19 +/− 23 days; p < 0.001) [20]. In
another study, investigators described higher maximum
daily dose of furosemide (3.2 +/− 0.58 mg/kg vs. 2.45
+/− 0.79 mg/kg; p = 0.05), longer duration of treatment
(17 +/− 8.3 days vs. 3.4 +/− 2.1 days; p < 0.001), and
higher cumulative dose exposures (26.9 +/− 13.7 mg/kg
vs. 6.17 +/− 4 mg/kg; p < 0.001) in infants with SNHL
than in infants with normal hearing [22]. A third
study reported a longer duration of furosemide treat-
ment in infants with SNHL compared to those with
normal hearing (17.5 +/− 10 days vs. 7 +/− 4.9 days;
p = 0.002) [27].
Quality assessment
We assessed the quality of each study based on the risk
of bias in the seven domains of the ROBINS-I tool for
non-randomized studies (Table 3). The risk of bias in
the McCann study is included in Table 4 using the
Cochrane Risk of Bias Tool. The primary determining
factor for the assessment of moderate or serious risk of
bias was whether an appropriate analysis method was
used that controlled for important perinatal factors, such
as severity of illness, duration of hospitalization, birth
weight, gestational age, and co-morbidities known to be
risk factors for hearing loss. We considered two studies
to have a critical risk of bias due to grouping furosemide
exposure with other medications as a single variable
termed “ototoxins” [19, 29]. There was no pattern relat-
ing quality to the results of the studies (i.e., both positive
and negative studies included a mix of moderate and
serious risks of bias).
Strength of evidence
We determined that the strength of evidence for the
association of SNHL and furosemide exposure in prema-
ture infants is low based on our review of the existing
Fig. 1 PRISMA flow diagram for inclusion and exclusion of studies [71]
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Table 2 Summary of studies examining risk of hearing loss in premature infants
Study (Year) Design Population and Sample Size Outcome Measure Results
Mjoen (1982)
[19]
cohort 60 high-risk infants
27–44 weeks GA
ABR testing in NICU
and follow-up visits
• 4 infants with evidence of SNHL.
• 3/4 infants exposed to ototoxic
medications (furosemide and/or
aminoglycoside).
McCann (1985)
[18]
randomized
controlled
17 premature infants with
BPD (7 infants received
furosemide and 10 infants
received placebo)
Audiology screen at
discharge and
follow-up visits
• Normal hearing in all infants.
Salamy (1989)
[20]
cohort GA 24–34 weeks ABR in NICU and follow-up;
behavioral audiometry from
3 months to 4 years
• Infants with SNHL received greater
amounts of furosemide for longer
durations, in combination with
aminoglycoside or vancomycin
therapy (p < 0.001 for all factors).
Brown (1991)
[21]
case-control 35 infants with SNHL and
70 matched hearing-intact
controls
BAER testing prior to
discharge from NICU
• 17/35 (49%) infants with SNHL
and 6/70 (9%) controls were
exposed to furosemide (p < 0.0001).
Borradori (1997)
[22]
case-control 8 children with progressive bilateral
deafness born preterm (GA≤ 34 weeks)
with 16 controls matched on GA and BW
and 15 controls matched on perinatal
complications
ABR at NICU discharge
and follow-up
• 8/8 (100%) infants with SNHL and
13/15 (87%) controls received
furosemide (NS).
• Mean duration (p < 0.001), total
cumulative dose (p < 0.001), and
maximum daily dose (p = 0.05)
were higher in SNHL group.
Ertl (2001) [23] case-control 22 premature infants with SNHL and 25
controls matched on GA, BW, and perinatal
factors associated with hearing loss
OAE test and ABR if failed
OAE
• 4/22 (18%) infants with SNHL
and 1/25 (4%) controls received
furosemide (p < 0.01).
Rais-Bahrami
(2004) [24]
cohort 57 infants who received furosemide
and 207 infants who did not receive
furosemide
OAE, ABR, or both
prior to NICU discharge
• No difference in abnormal hearing
screen in furosemide and non-
furosemide groups (16% vs. 16%;
p = 0.95).
Xoinis (2007)
[25]
case-control 71 infants with SNHL, 24 with auditory
neuropathy,and 95 controls matched
on GA, BW, and birth year
ABR and OAE • Higher exposure to furosemide
in SNHL group (51%) and AN
group (96%) compared to
control group (32.6%) (p < 0.05)
for both comparisons.
Coenraad (2011)
[26]
case-control 9 infants with hearing loss and 36 controls
matched on GA, gender, and birth year
ABR screening prior to NICU
discharge and repeat ABR and
OAE at follow-up visit for
failed screening.
• No differences in furosemide
exposure between groups
(44% vs. 25%; p = 0.56).
Martinez-Cruz
(2012) [27]
case-control 6 children with SNHL and 87
normal-hearing controls with
birth weights < 750 g
BAER screening and OAE at
follow-up visits for failed
initial screening
• 6/6 (100%) infants with SNHL
and 45/87 (52%) control infants
received furosemide (p = 0.002).
• Longer average duration of
furosemide in SNHL infants who
received furosemide compared
with controls (18 days vs. 7 days).
Rastogi (2013)
[28]
cohort Infants with BW < 1500 g. ABR prior to NICU discharge;
Follow-up at 2 years for failed
screening to determine
hearing status
• No association with furosemide
and hearing loss when adjusting
for BW, GA, and other perinatal
risk factors (OR 1.18; p = 0.3).
Wang (2017)
[29]
cohort Included all infants with BW ≤ 1500 g. 297
infants with normal hearing and 12 infants
with hearing loss
OAE before discharge and
BAER at 3 months corrected
age if failed initial screen
• Exposure to ototoxins (furosemide
and/or gentamicin) was associated
with hearing loss (OR 3.62; 95%
CI 1.67–7.82).
Legend: GA Gestational Age, ABR Auditory brainstem response, BPD Bronchopulmonary dysplasia, SNHL Sensorineural hearing loss, BAER Brainstem auditory
evoked response, NICU Neonatal Intensive Care Unit, BW Birthweight, NS Non-significant, OAE Otoacoustic emission, AN Auditory neuropathy, ANSD Auditory
neuropathy spectrum disorder, OR Odds ratio, CI Confidence Interval
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literature. This judgement is based on the high risk of
bias in the observational studies, which often did not
adequately account for the severity of illness in infants
exposed to furosemide, and the inconsistency in the re-
sults. Furthermore, there is a problem with the direct-
ness of comparisons as infants exposed to furosemide
are also more likely to receive additional interventions
which may increase the risk of SNHL, such as concomi-
tant ototoxic medications and mechanical ventilation.
According to the Agency for Healthcare Research and
Quality (AHRQ), a low grade indicates “low confidence
that the evidence reflects the true effect [and] further
research is likely to change the confidence in the esti-
mate of effect and is likely to change the estimate” [17].
It is clear that further clinical trials are needed to ad-
equately assess the risk of SNHL in premature infants
exposed to furosemide.
Key question 2: Does exposure to furosemide in
premature infants increase the risk of nephrocalcinosis/
nephrolithiasis?
No randomized controlled trials of furosemide in prema-
ture infants have been performed that include outcome
data on the incidence of NC/NL. We identified 20
cohort studies examining the association of furosem-
ide exposure and NC/NL [30–49]. The results of the
studies were mixed; however, 12 of the 20 studies
found an association between furosemide and NC/NL
[30–32, 34–37, 40, 41, 44, 46, 47, 49]. All studies
were performed at single centers, except one, which
included infants from two centers [40]. Three of the
studies resembled case series in that there was no in-
clusion of adequate control groups without NC: one
of these studies found an association of furosemide
with NC and two studies did not [30, 38, 42].
Table 3 Quality assessment of observational studies examining risk of hearing loss in premature infants
Study (Year) Risk of Bias (Low, Moderate,
Serious, Critical, No Information)
Comments
Mjoen (1982) [19] Critical Critical risk of bias in classification of interventions domain: ototoxic
medications grouped as one variable (i.e., furosemide not identified
as a single risk factor).
Salamy (1989) [20] Moderate Confounding well-accounted for by assessing “neonatal status”
based on duration of hospitalization, days of assisted ventilation,
radiography and lab results, etc.
Brown (1991) [21] Serious Serious risk of bias in confounding domain: Selection of variables
included in the multivariate analyses based solely on results of
univariate analyses and did not adequately account for severity
of illness in each group.
Borradori (1997) [22] Moderate Confounding well-accounted for by the creation of two control
groups based on BW/GA and perinatal complications related to risk
of ototoxicity.
Ertl (2001) [23] Serious Serious risk of bias in confounding domain: infants not matched on
severity of illness or co-morbidities associated with hearing loss.
Rais-Bahrami (2004) [24] Serious Serious risk of bias in confounding domain: no adjustment for perinatal
factors related to hearing loss.
Xoinis (2007) [25] Serious Serious risk of bias in confounding domain: infants not matched on
severity of illness or co-morbidities associated with hearing loss.
Coenraad (2011) [26] Serious Serious risk of bias in confounding domain: infants not matched on
severity of illness or co-morbidities associated with hearing loss.
Martinez-Cruz (2012) [27] Serious Serious risk of bias in confounding domain: infants not matched on
severity of illness or co-morbidities associated with hearing loss.
Rastogi (2013) [28] Moderate Confounding well-accounted for in multivariate analyses, which adjusted
for GA, BW, and other known perinatal risk factors for hearing loss.
Wang (2017) [29] Critical Critical risk of bias in classification of interventions domain: ototoxic
medications grouped as one variable (i.e., furosemide not identified
as a single risk factor).
Legend: BW Birth weight, GA Gestational age
Table 4 Risk of bias in trials examining risk of hearing loss in premature infants
Study (Year) Risk of Bias (High, Low, Unclear)
Random Sequence
Generation
Allocation
Concealment
Blinding of Participants
and Personnel
Blinding of Outcome
Assessment
Incomplete
Outcome Data
Selective
Reporting
Other
Bias
McCann (1985) [18] Low Low Low Low High Unclear Low
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Table 5 summarizes the population characteristics,
sample size, outcome measures, and results from each
study. There was considerable variability in the inclusion
criteria, the timing of renal ultrasonography, and
duration of long-term follow-up. However, all of the
reviewed studies included premature infants with sono-
graphic evidence of NC/NL prior to discharge from the
NICU. Of the studies that included subsequent ultra-
sounds after NICU discharge, complete resolution of
NC occurred in 44–100% of infants by 2 years of age
[31, 33, 35, 36, 38, 39, 42, 46–49]. However, these
data on outcomes are incomplete, as they do not
include infants with the most severe disease, who
expired during their NICU hospitalization, and infants
lost to follow-up after discharge.
A dose-response relationship between furosemide
and NC/NL was evaluated in 8 studies [33, 34, 38,
39, 41, 42, 44, 46]. Half of these studies found no as-
sociation between dose and the development of NC/
NL. Two studies found no difference in average daily
dose or duration of furosemide between infants with
NC and infants without NC [33, 34]. Investigators re-
ported no difference in cumulative dose or duration
of treatment between infants with resolution of NC
compared to those with persistent findings of NC
[38]. An additional study found no difference in me-
dian total dose of furosemide before detection of NC
and in those infants without NC in another study
[41]. In contrast, one study found that infants with
resolution of NC received lower daily dosages of fur-
osemide than did those with persistent NC (p < 0.05)
and another determined that mean cumulative doses
of furosemide were significantly higher in infants with NC
than in those without NC (18.8 mg vs 5.0 mg; p: 0.001)
[39, 42]. A single center study found higher cumulative
doses of furosemide in infants with development of NC
than in those without NC (mean +/− standard deviation:
102.2 +/− 118.2 mg vs 32.3 +/− 81.1 mg; p = 0.001) [44].
Investigators identified exposure to furosemide with
cumulative dose > 10 mg/kg was the strongest independ-
ent risk factor for NC in a multivariable analysis of prema-
ture infants (OR 48.1 (95% CI 4.0–585); p < 0.01) [46].
Quality assessment
We assessed the quality of each study based on the risk
of bias in the seven domains of the ROBINS-I tool for
non-randomized studies (Table 6). We determined that
one study had a critical risk of bias and resembled a case
series in its lack of the use of a control group [30]. The
most common reason we considered a study to have a
serious risk of bias was the absence of adjustment for
severity of illness. Three studies used multivariable ana-
lysis to control for the high correlation of cumulative
furosemide exposure with birthweight, duration of
mechanical ventilation, and severity of BPD, all variables
that are independently associated with the development
of NC/NL [34, 41, 46]. One study found that furosemide
exposure was the strongest independent risk factor for
NC, despite controlling for multiple markers of illness
severity. However, two studies that considered the tem-
poral relationship between furosemide and NC found no
difference in mean dose of furosemide before detection
of NC on renal ultrasound in infants who did or did not
subsequently develop NC [34, 41]. There was no pattern
relating quality to the results of the studies (i.e., both
positive and negative studies included a mix of moderate
and serious risks of bias).
Strength of evidence
We determined that the strength of evidence for the
association of NC/NL and furosemide exposure in pre-
mature infants is low based on our review of the existing
literature. No clinical trials of furosemide have examined
the outcome of NC/NL. There is a high risk of bias in
the numerous observational studies reviewed as only a
few studies accounted for other renal stone-promoting
factors, such as concomitant medication use and supple-
mentation of calcium, phosphorus, and vitamin D to re-
duce the risk of osteopenia of prematurity. The AHRQ
classifies evidence as indirect if “it uses intermediate or
surrogate outcomes instead of ultimate health outcomes;
one body of evidence links the intervention to inter-
mediate outcomes and another body of evidence links
the intermediate to most important (health or ultimate)
outcomes.” (p. 515) The endpoint of NC/NL is likely a
surrogate outcome for chronic kidney disease and car-
diovascular disease, which were detected in a minority
of infants included in the studies. Although clinical trials
are needed to determine the relationship of furosemide
and NC/NL, adequate long-term follow-up will also be
required to determine any lasting effects of NC/NL on
renal and cardiovascular health.
Discussion
We found no evidence that furosemide exposure in-
creases the risk of SNHL or NC/NL in premature
infants. We determined that the strength of evidence for
the association of these outcomes with furosemide
exposure is low. With the exception of one randomized
controlled trial including SNHL as an outcome, all
reviewed studies were cohort or case-control studies.
These studies’ observational designs left many important
potential confounding variables not well-accounted for,
such as severity of illness, duration of mechanical venti-
lation, and concomitant medication exposures. Some of
the included cohort studies were of high quality and
used multivariable analyses to account for confounding,
but randomized controlled trials of furosemide are
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Table 5 Summary of studies examining risk of nephrocalcinosis/nephrolithiasis (NC/NL) in premature infants
Study (Year) Design Population and Sample Size Outcome Measure Results Summary
Hufnagle (1982) [30] cohort 10 premature infants with NC RUS during NICU
admission
• All infants received furosemide
of at least 2 mg/kg/day for at
least 12 days prior to NC.
Woolfield (1988) [31] cohort 36 infants with BW ≤ 1500 g RUS at 12 months of age • 3/32 (9%) infants had NC on
RUS and had received chronic
furosemide with doses ranging
from 2 to 8 mg/kg/day.
• NC resolved in 2/3 (67%) cases;
1 died of unrelated causes.
Jacinto (1988) [32] cohort 31 infants with BW < 1500 g RUS in third week of life
and every 3 week
thereafter until NICU
discharge
• NC was diagnosed in 20/31 (64%)
of infants.
• Exposure to furosemide was more
common in NC group (65% vs 9%;
p < 0.001).
Ezzedeen (1988) [33] cohort 17 premature infants with NC treated with
furosemide; 3 premature infants treated with
furosemide without NC (control group)
RUS during NICU
admission
• No difference in average daily dose
or duration of furosemide in NC
group compared to control group.
Short (1991) [34] cohort 79 infants with GA < 32 weeks Serial RUS • 21/79 (27%) of infants diagnosed
with NC.
• No difference in mean total dose
of furosemide.
Downing (1991) [35] cohort 117 infants with BW < 1750 g and BPD
treated with furosemide
RUS prior to discharge and
in 3–6 month intervals for
positive findings of NC/NL
• 20/117 (17%) had evidence of
NC/NL on RUS prior to discharge.
• Infants maintained on furosemide
were more likely to have persistent
NC/NL compared to those for whom
furosemide was stopped (p < 0.001).
Downing (1992) [36] cohort 27 infants with BW < 1500 g enrolled into 3
groups: 1) not exposed to furosemide (n = 7);
2) received furosemide without NC (n = 10);
and 3) received furosemide with NC (n = 10)
RUS and laboratory testing
for glomerular and tubular
kidney function
• Infants in group 3 had lower creatinine
clearance (reduced glomerular function)
and higher tubular dysfunction
compared to infants in group 1 and 2.
Stafstrom (1992) [37] cohort 11 premature infants with post-hemorrhagic
hydrocephalus treated with furosemide and
acetazolamide
Serial RUS • 5/11 (45%) infants with evidence of NC.
• No correlation between duration of
treatment, total dosage of medications,
and development of renal calculi.
Pope (1996) [38] cohort 13 premature infants with NC and exposed to
furosemide divided into 2 groups: resolution of
NC (n = 6) and persistent NC (n = 7).
Serial RUS • No difference in duration of or
cumulative dose of furosemide in
infants with resolution of NC
compared to those with persistence
of NC.
Saarela (1999) [39] cohort 129 infants with BW < 1500 g RUS at 2 weeks, 6 weeks,
and 3 months of life
• 26/129 (20%) of infants diagnosed
with NC.
• The mean cumulative doses of
furosemide were significantly higher
in infants with NC compared to those
without NC (19 mg vs 5 mg; p < 0.001).
Schell-Feith (2000) [40] cohort 215 infants with GA < 32 weeks RUS at 4 weeks of life
and at term
• NC diagnosed in 50/150 (33%) of
infants at 4 weeks of life and 83/201
(41%) at term (NS).
• At term, furosemide exposure was
higher in those with NC (32%)
compared to those without NC
(18%) (p < 0.001).
Narendra (2001) [41] cohort 101 infants with GA < 32 weeks
or BW < 1500 g
RUS at 1 month of age and
at term or NICU discharge
• 16/101 (16%) diagnosed with NC.
• The median total dose of furosemide
was not significantly different before
detection of NC on term RUS and in
infants without NC (p = 0.75).
Hoppe (2002) [42] cohort 16 infants with GA < 37 weeks
and diagnosed with NC
RUS during NICU admission
and every 3–6 months
following discharge
• NC persisted in 4/12 (33%) infants who
received follow-up.
• Infants with resolution of NC received
lower dosages of furosemide
compared to those with persistent
NC (p < 0.05).
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urgently needed to assess the risks of SNHL and NC/NL
in premature infants.
Despite the proposed benefits and biological plausibil-
ity of using furosemide to improve respiratory outcomes,
the efficacy of furosemide in premature infants has not
been established. A Cochrane systematic review examin-
ing loop diuretics for preterm infants found no evidence
to support an improvement in long-term outcomes,
including BPD [50]. However, results from the review in-
dicated that chronic administration of furosemide (i.e.,
at least 7 days) improves oxygenation and lung compli-
ance in premature infants with established BPD. The
review emphasizes the need for randomized clinical
trials to assess the effects of furosemide administration
on morbidity and mortality.
Notwithstanding the absence of data supporting the
efficacy of furosemide, the medication is commonly used
by clinicians in the neonatal intensive care unit (NICU)
with the intention to improve oxygenation and wean
respiratory support in premature infants. A cohort study
from more than 300 NICUs in the U.S. found that
furosemide was the fifth most common drug used be-
tween the years 2005 to 2010 in premature infants with
birth weights < 1000 g, with approximately 50% of these
infants exposed to at least one dose of furosemide dur-
ing their initial hospitalization [51]. Although other diur-
etic medications are used in the NICU for similar
indications, furosemide is by far the most commonly
used diuretic in the NICU, accounting for 93% of diur-
etic use [52]. Furosemide is also variably used in the
NICU setting. A cohort study of infants with birth
weights < 1500 g from more than 200 U.S. NICUs over a
15 year period found considerable variability in the
percentage of infants exposed to at least one dose of fur-
osemide at each particular site, with a median exposure
by site of 33% and a range of 0 to 75%. The observations
from this study emphasize the lack of a universally
accepted standard governing when to expose an infant
in the NICU to furosemide and indicate that at some
centers, no exposure to furosemide is an option [52].
Additional potential adverse outcomes of furosemide
use in premature infants include metabolic bone disease
Table 5 Summary of studies examining risk of nephrocalcinosis/nephrolithiasis (NC/NL) in premature infants (Continued)
Study (Year) Design Population and Sample Size Outcome Measure Results Summary
Hein (2004) [43] cohort 114 infants with BW < 1500 g divided into 2
groups: 1) NC (n = 20); 2) without NC (n = 94).
20 infants from control group matched to NC
group based on BW and GA.
RUS every 2 weeks
during NICU admission
• No difference in duration of furosemide
therapy between groups.
Ketkeaw (2004) [44] cohort 36 infants with GA < 32 weeks and
BW < 1250 g
RUS prior to NICU
discharge
• 14/36 (39%) were diagnosed with NC.
• The mean cumulative dose and mean
duration of furosemide was higher in
infants with NC compared to those
without NC (102 mg vs 32 mg;
p = 0.001 and 39 vs 7 days; p = 0.001).
Cranefield (2004) [45] cohort Cohort of infants enrolled in randomized trial
of two regimens of dexamethasone for the
prevention of BPD.
RUS on study entry, day of
life 28, and at discharge or
36 weeks postmenstrual age
• 15/18 (83%) of infants for whom
complete data were available were
diagnosed with NC prior to discharge
or 36 weeks postmenstrual age.
• Furosemide was used infrequently in
the trial. 7/8 (88%) of the infants who
never received furosemide
developed NC.
Gimpel (2010) [46] cohort 55 infants with GA < 32 weeks and
BW < 1500 g
RUS obtained after the
first month of life
• 15/55 (27%) of infants were
diagnosed with NC.
• The strongest independent risk factor
for NC was furosemide therapy with
cumulative dose > 10 mg/kg (OR 48.1
(95% CI 4.0–585); p < 0.01).
Chang (2011) [47] cohort 102 infants with GA < 34 weeks and BW <
1500 g
RUS at term or prior to NICU
discharge
• 6/102 (6%) of infants were diagnosed
with NC.
• Exposure to furosemide was more
common in the NC group compared
to the group without NC (33% vs 3%;
p = 0.027).
Lee (2014) [48] cohort 52 infants with BW < 1500 g RUS at 4 and 8 weeks of life • Exposure to furosemide did not differ
significantly between infants with NC
and those without NC.
Mohamed (2014) [49] cohort 97 infants with GA ≤ 34 weeks RUS at first week of life,
at term, and at one year
corrected age
• Exposure to furosemide was more
common in the NC group compared
to the group without NC (50% vs 16%;
p = 0.003).
Legend: BW Birth weight, GA Gestational age, OR Odds ratio, CI Confidence interval, BPD Bronchopulmonary dysplasia
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(osteopenia) of prematurity and electrolyte abnormalities
related to urinary loss of sodium, chloride, and calcium
[53–55]. As with other adverse outcomes, the etiology of
metabolic bone disease in premature infants likely has
many causes, and infants with severe illness often have
multiple risk factors such as insufficient phosphorus
intake, vitamin D deficiency, prolonged immobilization,
mechanical ventilation, and exposure to steroids and
antibiotics [56–58]. However, there is a lack of consen-
sus on the definition of metabolic bone disease of
prematurity, with some definitions relying on serum
mineral levels and others based on radiographical find-
ings [59]. As a result, this review did not focus on
metabolic bone disease of prematurity as an outcome of
interest in premature infants exposed to furosemide.
Existing safety data on the use of furosemide in adults
and children cannot be extrapolated to premature
infants due to higher extracellular fluid volume per unit
body weight, immature hepatic and renal function, and a
more permeable blood-brain barrier in premature
infants, variables which can alter the rates of drug ab-
sorption, distribution, metabolism, and elimination [60].
Four studies of furosemide pharmacokinetics in prema-
ture infants demonstrate significant variability in the
volume of distribution, clearance, and half-life of the
drug based on gestational age at birth, birth weight, and
Table 6 Quality assessment of observational studies examining risk of nephrocalcinosis/nephrolithiasis (NC/NL) in premature infants
Study (Year) Risk of Bias (Low, Moderate,
Serious, Critical, No Information)
Comments
Hufnagle (1982) [30] Critical Critical risk of bias in confounding domain: no statistical tests
performed in the analysis to test association of NC and furosemide.
Critical risk of bias in selection of participants into the study: All
infants were exposed to furosemide and had NC; lack of control group.
Woolfield (1988) [31] Serious Serious risk of bias in confounding domain: no statistical tests
performed in the analysis to test association of NC and furosemide.
Jacinto (1988) [32] Serious Serious risk of bias in confounding domain: Lower BW and GA associated
with outcome (NC), along with exposure to furosemide. Did not control
for severity of illness.
Ezzedeen (1988) [33] Serious Serious risk of bias in confounding domain: no adjustment for severity of
illness; small number of infants in control group.
Short (1991) [34] Moderate Multivariate analyses controlling for other risk factors for NC. Dose-response
relationship evaluated.
Downing (1991) [35] Moderate All infants screened for the outcome had a diagnosis of chronic lung
disease; high percentage of follow-up imaging obtained.
Downing (1992) [36] Moderate Robust comparators; long-term follow-up.
Stafstrom (1992) [37] Serious Serious risk of bias in confounding domain: no statistical tests performed
in the analysis to test association of NC and furosemide. No reporting of
frequency of NC in infants with post-hemorrhagic hydrocephalus not
exposed to furosemide.
Pope (1996) [38] Moderate Similar severity of illness in each group; long-term follow up with serial
ultrasounds. Dose-response relationship evaluated.
Saarela (1999) [39] Moderate Dose-response relationship evaluated.
Schell-Feith (2000) [40] Moderate Large sample size. Control group without NC included.
Narendra (2001) [41] Moderate Multivariate analyses controlling for other risk factors for NC. Dose-response
relationship evaluated.
Hoppe (2002) [42] Serious Serious risk of bias in confounding domain: Lack of control group without NC.
Hein (2004) [43] Moderate Large sample size with appropriate control groups.
Ketkeaw (2004) [44] Moderate Appropriate control group included. Dose-response relationship evaluated.
Cranefield (2004) [45] Moderate All infants with comparable severity of illness.
Gimpel (2010) [46] Moderate Multivariate analyses controlling for other risk factors for NC.
Dose-response relationship evaluated.
Chang (2011) [47] Serious Serious risk of bias in confounding domain: no adjustment for severity
of illness. Low incidence of NC in sample.
Lee (2014) [48] Serious Serious risk of bias in confounding domain: no adjustment for severity of illness.
Mohamed (2014) [49] Serious Serious risk of bias in confounding domain: no adjustment for severity of illness.
Legend: BW Birth weight, GA Gestational age
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postnatal age [61–64]. The limited available data on
pharmacokinetics and safety have led to a growing
recognition of the need for clinical trials in premature
infants to determine the safety and efficacy of thera-
peutic agents, such as furosemide [65, 66].
A phase II clinical trial by the Pediatric Trials Network
is underway to better understand the safety of furosem-
ide in premature infants at risk of BPD [67]. This trial
will enroll premature infants born < 29 weeks’ gestation
and receiving positive airway pressure or mechanical
ventilation on 7–28 days postnatal age. The study design
includes a dose escalation schedule with three cohorts
randomized to placebo or furosemide. Primary outcomes
will include safety information on SNHL (based on
BAER prior to discharge) and NC/NL determined by
serial renal ultrasounds. Secondary outcomes will as-
sess effectiveness of early furosemide in the preven-
tion of BPD or death. The dose escalation design of
the study will allow for evaluation of a dose-response
relationship of furosemide and the outcomes of SNHL
and NC.
Premature infants, particularly those born small for
gestational age, are at an increased risk for cardiovascu-
lar and renal disease in later life, likely due to a combin-
ation of genetic and environmental factors [68]. It is
important to understand whether furosemide exposure,
with or without evidence of NC/NL, contributes to the
development of chronic kidney disease in these infants.
Future studies investigating the safety of furosemide in
premature infants will need to consider long-term
surveillance of renal disease, particularly in those who
develop NC/NL. The study design of trials investigat-
ing furosemide in the neonatal population should
incorporate serial renal sonography, blood pressure
measurements, urinalysis for proteinuria, and serum
creatinine, where appropriate, to determine renal
function over time.
This systematic review was limited by the inclusion of
only one randomized controlled trial. The remaining
studies were cohort and case-control studies, which by
the nature of their study design are unable to demon-
strate a causal role. While many randomized controlled
trials of furosemide in premature infants have been
performed, very few included data on safety outcomes,
which were the subject of this review. In addition, the
search strategy was limited to studies published in
English may not have included all available studies; for
instance, we found that some studies included from our
review of reference lists used variable spellings of
“furosemide.” The field of neonatology has changed
dramatically over the past 20 years with the introduction
of antenatal steroids, surfactant replacement therapy,
and non-invasive ventilation strategies. These practices
have resulted in significantly improved survival and
reduced morbidities in premature infants [69, 70].
Therefore, results from studies included in this review
which were performed decades ago may not be applic-
able to infants born in the current era. Finally, we were
unable to perform a meta-analysis of the included obser-
vational studies due to a lack of uniformity in outcome
definitions, population characteristics, and length of
follow-up.
Conclusions
This systematic review of the safety of furosemide in
premature infants focuses on the outcomes of SNHL
and NC/NL. Irrespective of the efficacy of furosemide in
premature infants, the existing literature on safety out-
comes depends almost entirely on observational data.
Furthermore, few studies used analytic approaches to
control for confounding causes of additional risk of
SNHL and NC/NL on premature infants exposed to
furosemide. The strength of evidence for the association
of SNHL and NC/NL and furosemide is therefore deter-
mined to be low. Further randomized controlled trials
with robust safety measures, such as the ongoing PTN
trial, are urgently needed to assess the safety of furosem-
ide in premature infants.
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